Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...

The German Diabetes Society (DDG) issued a warning concerning a rise in pregnancies among women using injectable medications ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior t ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

From life-changing medical advancements to colorful auroras, this year has been packed with incredible science. It was hard ...

By mode of administration, the injectable pens segment accounted for the highest revenue-grossing segment in the global ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.